Evidence map›Paper›PMID 34263489›Full record

ArticleNMR in biomedicine2021

Synthesis of [1-

Natsuko Miura, Chandrasekhar Mushti, Deepak Sail, Jenna E AbuSalim, Kazutoshi Yamamoto, Jeffrey R Brender, Tomohiro Seki, Deyaa I AbuSalim, Shingo Matsumoto, Kevin A Camphausen and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NMR in biomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Clinical Translation of HyperpolarizedAJNR. American journal of neuroradiology · 2025
    Review
  3. Quo Vadis HyperpolarizedZeitschrift fur medizinische Physik · 2025
    Review
  4. Hyperpolarized MRI theranostics in cancer.Frontiers in oncology · 2025
    Article
  5. Review
  6. RapidAnalytical chemistry · 2022
    Article
  7. Review
  8. Simple Esterification of [1-ACS chemical biology · 2021
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Natsuko MiuraRadiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Chandrasekhar MushtiChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Deepak SailChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Jenna E AbuSalimRadiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Kazutoshi YamamotoRadiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Jeffrey R BrenderRadiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Tomohiro SekiRadiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Deyaa I AbuSalimDepartment of Chemistry, Indiana University, Bloomington, Indiana, USA.
Shingo MatsumotoRadiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Kevin A CamphausenRadiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Murali C KrishnaRadiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Rolf E SwensonChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Aparna H KesarwalaRadiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-8297-9643
National Institutes of Health · USIndiana University Bloomington · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Pre-clinical Development of Radiation Sensitizers for Patients with GlioblastomaZIASC010372 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI CAMPHAUSEN, KEVIN · 2009 to 2025
$12.0M
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLCP50CA217691 · NCI · EMORY UNIVERSITY · PI SICA, GABRIEL LARKIN · 2019 to 2024
$10.1M
Monitoring the interactions between cancer cell metabolism and radiation responseR00CA222493 · NCI · EMORY UNIVERSITY · PI KESARWALA, APARNA · 2019 to 2021
$747k
Japan Society for the Promotion of ScienceNational Institutes of Health Intramural Research ProgramNCI NIH HHS P30 CA138292NCI NIH HHS P50 CA217691NCI NIH HHS R00 CA222493NCI NIH HHS R00CA222493
6 · The paper itself

Abstract

Isocitrate dehydrogenase 1 (IDH1) mutations that generate the oncometabolite 2-hydroxyglutarate (2-HG) from α-ketoglutarate (α-KG) have been identified in many types of tumors and are an important prognostic factor in gliomas. 2-HG production can be determined by hyperpolarized carbon-13 magnetic resonance spectroscopy (HP-

Indexed as

Carbon-13 Magnetic Resonance SpectroscopyGlutaratesHCT116 CellsHumansKetoglutaric Acidsalpha-hydroxyglutarateGlutaratesKetoglutaric Acids2-hydroxyglutaratealpha-ketoglutaratecarbon-13 labeled metaboliteshyperpolarized carbon-13 nuclear magnetic resonance spectroscopyisocitrate dehydrogenase 1

Identifiers

PMID34263489
PMCPMC8492538
OpenAlexW3178862309

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.